Ftse Mib
34.870,18
0,40%
DAX
20.415,14
0,01%
S&P 500
6.075,52
-0,14%
NASDAQ
19.991,54
-0,22%
Bitcoin
101.699,40
0,50%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aldeyra Therapeutics Inc (ALDX) Aldeyra Therapeutics Inc (ALDX) Notizie

ALDX

Aldeyra Therapeutics (ALDX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALDX
DataOraFonteTitoloSimboloCompagnia
02/12/202413:00Business WireAldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
18/11/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
18/11/202413:00Business WireAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementNASDAQ:ALDXAldeyra Therapeutics Inc
14/11/202413:00Business WireAldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
07/11/202422:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
31/10/202412:00Business WireAldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingNASDAQ:ALDXAldeyra Therapeutics Inc
22/10/202402:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
03/10/202413:00Business WireAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
10/09/202422:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
05/09/202413:00Business WireAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
13/08/202400:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/202413:00Business WireAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
07/08/202422:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
01/08/202423:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALDXAldeyra Therapeutics Inc
20/06/202413:00Business WireAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202413:00Business WireAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
12/06/202413:00Business WireAldeyra Therapeutics to Host Investor Roundtable Q&ANASDAQ:ALDXAldeyra Therapeutics Inc
29/05/202413:00Business WireAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
08/05/202413:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202413:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202413:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202412:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202413:00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202423:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202413:00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202313:00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALDX

La tua Cronologia

BIT
UCG
Unicredit
BIT
BPE
Bper Banca
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
BC
Brunello Cucinelli
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
MONC
Moncler
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
OVS
Ovs
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network